Xinda Securities·2025-12-21 13:08Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The report highlights a recovery trend in the pharmaceutical market, driven by the passage of the revised Biological Safety Act in the U.S., which is expected to improve valuations and performance in the CXO sector [3][10] - The report emphasizes the potential for growth in the AI and healthcare sectors, particularly with the recent upgrade of Ant Group's AI health application, which has seen significant user engagement [3][10] - The upcoming JPM Healthcare Conference is anticipated to be a major catalyst for innovation in the pharmaceutical sector, with over 8,000 participants expected [3][10] Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's weekly return was -0.14%, ranking 22nd among 31 primary sub-industry indices, while the pharmaceutical commercial sector had the highest weekly return of 4.94% [3][10] - Over the past month, the sector's return was -2.50%, ranking 19th, with the pharmaceutical commercial sector again leading with a return of 4.68% [3][10] Policy Dynamics - On December 17, 2025, the National Health Commission released an action plan to enhance elderly care services, aiming to improve the care system by 2027 [3][10] - The National Medical Products Administration published guidelines for clinical trial institutions to enhance regulatory oversight [3][10] CXO and Life Sciences - Recommended leading CXO companies include WuXi AppTec, WuXi Biologics, and others, while domestic clinical CRO leaders such as Tigermed and others are also highlighted [3][10] - The life sciences upstream supply chain includes companies like BGI and others [3][10] AI + Healthcare - Key companies in AI healthcare models include Zhiyun Health and others, while AI imaging and diagnostics sectors also have notable players [4][10] High-end Medical Devices - Companies benefiting from the recovery in hospital procurement include Mindray and others, while domestic demand for consumer medical devices is gradually recovering [4][10] Innovative Drugs - Focus areas include small nucleic acids, ADCs, and dual/multi-antibody therapies, with recommended companies in each category [4][10]